Acceleron Pharma is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around $112.8 million.
Our top picks for where to buy Acceleron Pharma stock
How to buy Acceleron Pharma stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – XLRN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Acceleron Pharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Acceleron Pharma stock price (NASDAQ: XLRN)
Use our graph to track the performance of XLRN stocks over time.Acceleron Pharma shares at a glance
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $169.49 |
200-day moving average | $137.95 |
Wall St. target price | $178.88 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-4.20 |
Is it a good time to buy Acceleron Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Acceleron Pharma price performance over time
Historical closes compared with the close of $N/A from 2021-12-08
1 week (2024-07-16) | N/A |
---|---|
1 month (2024-06-23) | N/A |
3 months (2024-04-23) | N/A |
6 months (2024-01-23) | N/A |
1 year (2023-07-23) | N/A |
---|---|
2 years (2022-07-23) | N/A |
3 years (2021-07-27) | -100.00% |
5 years (2019-07-26) | -100.00% |
Acceleron Pharma financials
Revenue TTM | $112.8 million |
---|---|
Gross profit TTM | $-81,394,000 |
Return on assets TTM | -18.4% |
Return on equity TTM | -31.59% |
Profit margin | -226.01% |
Book value | $11.75 |
Market Capitalization | $10.9 billion |
TTM: trailing 12 months
Acceleron Pharma share dividends
We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.
Acceleron Pharma share price volatility
Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.1314. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).
Acceleron Pharma overview
Acceleron Pharma Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc.
Frequently asked questions
nullWhat percentage of Acceleron Pharma is owned by insiders or institutions?
Currently 11.697% of Acceleron Pharma shares are held by insiders and 88.283% by institutions. How many people work for Acceleron Pharma?
Latest data suggests 312 work at Acceleron Pharma. When does the fiscal year end for Acceleron Pharma?
Acceleron Pharma's fiscal year ends in December. Where is Acceleron Pharma based?
Acceleron Pharma's address is: 128 Sidney Street, Cambridge, MA, United States, 02139 What is Acceleron Pharma's ISIN number?
Acceleron Pharma's international securities identification number is: US00434H1086 What is Acceleron Pharma's CUSIP number?
Acceleron Pharma's Committee on Uniform Securities Identification Procedures number is: 00434H108
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question